Literature DB >> 20817282

Conditioning of the heart: from pharmacological interventions to local and remote protection: possible implications for clinical practice.

Shahar Lavi1, Ronit Lavi.   

Abstract

Ischemic preconditioning is a natural protective mechanism by which brief episodes of ischemia protect the heart or other organs from the deleterious effects of ischemia-reperfusion injury. Ischemic preconditioning was demonstrated in animals more than 20 years ago, and subsequent studies in humans showed a dramatic protective effect on the heart. This method did not translate into clinical practice partially due to difficulty in application of conditioning. At the same time, multiple drugs were assessed, but none proved to be beneficial in large scale studies for myocardial protection. Although multicenter studies are still lacking, it was recently demonstrated in reasonable sized studies that in patients undergoing percutaneous coronary interventions or suffering from myocardial infarction, remote ischemic conditioning has beneficial protective effect. With more studies we may see translation into clinical practice in the near future.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20817282     DOI: 10.1016/j.ijcard.2010.08.010

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  Long-term outcome following remote ischemic postconditioning during percutaneous coronary interventions-the RIP-PCI trial long-term follow-up.

Authors:  Shahar Lavi; Nour Abu-Romeh; Sabrina Wall; Mistre Alemayehu; Ronit Lavi
Journal:  Clin Cardiol       Date:  2017-01-11       Impact factor: 2.882

2.  Ischemic postconditioning during primary percutaneous coronary interventions-not ready for prime time.

Authors:  Shahar Lavi; Ronit Lavi
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

3.  Association of remote ischemic peri-conditioning with reduced incidence of clinical heart failure after primary percutaneous coronary intervention.

Authors:  Adetola Ladejobi; Max Wayne; Christian Martin-Gill; Francis X Guyette; Andrew D Althouse; Michael S Sharbaugh; Steven E Reis; Clifton W Callaway; John A Kellum; A J Conrad Smith; Catalin Toma; Oladipupo Olafiranye
Journal:  Cardiovasc Revasc Med       Date:  2016-12-15

4.  Myocardial infarct size and area at risk assessment in mice.

Authors:  Bjorn Redfors; Yangzhen Shao; Elmir Omerovic
Journal:  Exp Clin Cardiol       Date:  2012

5.  Plasma from human volunteers subjected to remote ischemic preconditioning protects human endothelial cells from hypoxia-induced cell damage.

Authors:  Nina C Weber; Isabelle Riedemann; Kirsten F Smit; Karina Zitta; Djai van de Vondervoort; Coert J Zuurbier; Markus W Hollmann; Benedikt Preckel; Martin Albrecht
Journal:  Basic Res Cardiol       Date:  2015-02-26       Impact factor: 17.165

6.  Activities of cardiac tissue matrix metalloproteinases 2 and 9 are reduced by remote ischemic preconditioning in cardiosurgical patients with cardiopulmonary bypass.

Authors:  Karina Zitta; Patrick Meybohm; Berthold Bein; Matthias Gruenewald; Fabian Lauer; Markus Steinfath; Jochen Cremer; Kai Zacharowski; Martin Albrecht
Journal:  J Transl Med       Date:  2014-04-08       Impact factor: 5.531

7.  Remote Ischemic Preconditioning Enhances the Expression of Genes Encoding Antioxidant Enzymes and Endoplasmic Reticulum Stress-Related Proteins in Rat Skeletal Muscle.

Authors:  Ui Jun Park; Hyoung Tae Kim; Won Hyun Cho; Jae Hyoung Park; Hye Ra Jung; Min Young Kim
Journal:  Vasc Specialist Int       Date:  2016-12-31

8.  Intralipid postconditioning in patients of cardiac surgery undergoing cardiopulmonary bypass (iCPB): study protocol for a randomized controlled trial.

Authors:  Yuan Yuan; Hui Xiong; Yan Zhang; Hong Yu; Rong-Hua Zhou
Journal:  Trials       Date:  2020-11-23       Impact factor: 2.279

9.  Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient.

Authors:  Mozow Y Zuidema; Kevin C Dellsperger
Journal:  Cardiorenal Med       Date:  2012-03-30       Impact factor: 2.041

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.